Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT01423110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Sporadic Inclusion Body Myositis

Interventions

BIOLOGICAL: BYM338
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals